When did ARBUTUS BIOPHARMA CORP (ABUS) report earnings last quarter?
ARBUTUS BIOPHARMA CORP (ABUS) last reported earnings on 3/23/2026.
ARBUTUS BIOPHARMA CORP (ABUS) Earnings History & Surprises
NASDAQ:ABUS • CA03879J1003
Current stock price
4.15 USD
-0.15 (-3.49%)
At close:
4.1957 USD
+0.05 (+1.1%)
After Hours:
ABUS Earnings overview
Past quarterly earnings results for ARBUTUS BIOPHARMA CORP (ABUS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Apr 30, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.04
- Revenue Estimate
- 408K
Last Reported
Most Recent- Release Date
- Mar 23, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$0.02
- EPS Surprise
- 43.98%
- Revenue Surprise
- 47.20%
Beat Rate
Last 8 Quarters 44%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.02 | -0.04 | 43.98% | 71.43% | 1.051M | 714K | 47.20% | -33.23% |
| Q3 2025 | -0.04 | -0.03 | -26.50% | 55.56% | 529K | 1.292M | -59.06% | -60.49% |
| Q2 2025 | 0.01 | -0.05 | 120.64% | 109.09% | 10.739M | 1.622M | 562.08% | 522.19% |
| Q1 2025 | -0.13 | -0.11 | -23.26% | -30.00% | 1.764M | 1.815M | -2.81% | 15.14% |
| Q4 2024 | -0.07 | -0.08 | 14.22% | 41.67% | 1.574M | 1.595M | -1.32% | -26.62% |
| Q3 2024 | -0.09 | -0.10 | 6.73% | 25.00% | 1.339M | 1.898M | -29.45% | -71.25% |
| Q2 2024 | -0.11 | -0.10 | -11.41% | -10.00% | 1.726M | 1.79M | -3.58% | -62.89% |
| Q1 2024 | -0.10 | -0.11 | 10.87% | - | 1.532M | 2.769M | -44.67% | -77.09% |
| Q4 2023 | -0.12 | -0.12 | 0.30% | 14.86% | 2.145M | 4.889M | -56.13% | -65.68% |
| Q3 2023 | -0.12 | -0.12 | -3.38% | - | 4.658M | 4.847M | -3.90% | -21.71% |
| Q2 2023 | -0.10 | -0.11 | 12.62% | - | 4.651M | 6.31M | -26.29% | -67.34% |
| Q1 2023 | -0.10 | -0.14 | 27.91% | 9.09% | 6.687M | 6.149M | 8.75% | -46.84% |
| Q4 2022 | -0.14 | -0.14 | -3.12% | 6.03% | 6.25M | 6.299M | -0.78% | 94.70% |
| Q3 2022 | -0.12 | -0.13 | 8.09% | 50.00% | 5.95M | 9.561M | -37.77% | 78.14% |
| Q2 2022 | -0.10 | -0.13 | 22.19% | 56.52% | 14.24M | 6.903M | 106.29% | 511.16% |
| Q1 2022 | -0.11 | -0.16 | 32.60% | 47.62% | 12.58M | 4.455M | 182.38% | 496.21% |
| Q4 2021 | -0.15 | -0.19 | 22.60% | 34.78% | 3.21M | 2.932M | 9.48% | 34.31% |
| Q3 2021 | -0.24 | -0.24 | 1.14% | 11.11% | 3.34M | 2.432M | 37.34% | 119.74% |
| Q2 2021 | -0.23 | -0.23 | -0.97% | 8.00% | 2.33M | 2.165M | 7.62% | 54.30% |
| Q1 2021 | -0.21 | -0.24 | 11.04% | 16.00% | 2.11M | 3.372M | -37.43% | 41.61% |
| Q4 2020 | -0.23 | -0.23 | -1.83% | - | 2.39M | 1.997M | 19.68% | - |
| Q3 2020 | -0.27 | -0.22 | -22.55% | - | 1.52M | 1.696M | -10.38% | - |
| Q2 2020 | -0.25 | -0.24 | -2.12% | - | 1.51M | 1.773M | -14.83% | - |
| Q1 2020 | -0.25 | -0.32 | 21.94% | - | 1.49M | 1.326M | 12.37% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
28.71%
Max EPS beat (4)
120.64%
Min EPS beat (4)
-26.50%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
136.85%
Max Revenue beat (4)
562.08%
Min Revenue beat (4)
-59.06%
Analysis
In the last 4 quarters, ABUS has beaten EPS estimates in 2 out of 4 releases
ABUS has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, ABUS has beaten the EPS estimates by 28.7% on average.
In the last 4 quarters, ABUS has beaten the revenue estimates by 136.9% on average.
Related analysis
ARBUTUS BIOPHARMA CORP / ABUS Earnings FAQ
Did ABUS stock beat earnings estimates in the most recent quarter?
ARBUTUS BIOPHARMA CORP (ABUS) beat EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does ABUS stock beat earnings estimates?
In the last 4 quarters, ARBUTUS BIOPHARMA CORP (ABUS) has beaten EPS estimates in 2 out of 4 releases.